Stock analysis, price data, and AI-powered insights for Elevance Health (ELV).
Elevance Health operates in the Healthcare sector and is a constituent of the S&P 500 index. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for ELV.
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). ELV Stock Intelligence Report. [stoxpulse.com/stocks/elv]
Disclaimer: The information on this page about Elevance Health (ELV) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Elevance Health.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
Earnings beat by 19%
Jun 30
PERU bought 1K shares
Jul 17
BOUDREAUX bought 680 shares
Jul 17
Teladoc Health Q2 Earnings Beat Estimates on Integ...
7h ago
ENSG Q2 Earnings Beat Estimates on Growing Occupan...
7h ago
StoxPulse AI results for ELV: Pulse Score 57/100. Primary sentiment trends from 15 news sources and 20 SEC filings indicate a bullish outlook.
Market Cap
$81.63B
P/E Ratio
14.9
EPS
$6.71
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Sep 25
+21.0%
Dec 25
+6.5%
Mar 26
+15.1%
Jun 26
+18.9%
Beat estimates 4 of 4 quarters (100%)
Sector
Healthcare
Industry
Managed Health Care
Teladoc Health Q2 Earnings Beat Estimates on Integrated Care Strength
ENSG Q2 Earnings Beat Estimates on Growing Occupancy, '26 View Raised
Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
Investors’ Favour Strengthens Elevance Health’s (ELV) Rebound
Humana Q2 Earnings Beat Estimates on Medical Membership Growth
Oakmark U.S. Large Value Strategy Q2 2026 Portfolio Review
Elevance Health Has Upside, But Not Yet A Buy
Centene Q2 Earnings Beat Estimates on Increasing Premiums